Skip to content

US · PLSE · MEDICAL - INSTRUMENTS & SUPPLIES

Pulse Biosciences, Inc. (PLSE) intrinsic value and stock valuation

$45.55as of 2026-11-21 · Mkt cap 2.62B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pulse Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values PLSE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PLSE’s statements →

Pulse Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Miami, FL 33131 pulsebiosciences.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$350K
20142025
Net income
-$-72.78M
20142025
Free cash flow
-$-54.44M
20142025
Total equity
$80.7M+28.6% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$350K$0.00$0.00$700K$1.42M
Operating income-$-76.94M-$-56.26M-$-43.57M-$-58.06M-$-63.01M
Net income-$-72.78M-$-53.59M-$-42.21M-$-58.51M-$-63.66M
EPSd-$-1.08M-$-917.64K-$-878.64K-$-1.72M-$-2.28M
Operating cash flow-$-54.12M-$-36.34M-$-33.04M-$-47.01M-$-54.1M
Capital expenditure-$-320K-$-120K-$-120K-$-400K-$-440K
Free cash flow-$-54.44M-$-36.47M-$-33.16M-$-47.41M-$-54.53M
Total assets$96.1M$132.5M$59.2M$77.9M$54.3M
Total debt$7.53M$8.9M$9.14M$76M$11.3M
Net debt-$-73.2M-$-109.14M-$-35.22M$14.8M-$-17.36M
Total equity$80.7M$114.9M$44.4M-$-2.25M$35.7M
Cash and short-term investments$80.7M$118M$44.4M$61.1M$28.6M
Income statement
20252024202320222021
Revenue$350K$0.00$0.00$700K$1.42M
Cost of revenue$1.61M$0.00$1.21M$11.9M$1.97M
Gross profit-$-1.26M$0.00-$-1.21M-$-11.24M-$-550K
Research and development expenses$44.7M$32.3M$27.8M$20.8M$28.6M
Selling, general and administrative expenses$32M$23.9M$15.8M$26M$33.8M
Other expenses-$-1.07M$0.00-$-1.21M$0.00$0.00
Operating expenses$75.7M$56.3M$42.4M$46.8M$62.5M
Cost and expenses$77.3M$56.3M$43.6M$58.8M$64.4M
Interest income$4.21M$2.67M$2.46M$0.00$0.00
Interest expense$0.00$0.00$1.1M$450K$650K
Depreciation and amortization$1.07M$1.18M$1.21M$1.35M$1.15M
Ebitda-$-71.71M-$-52.41M-$-39.9M-$-57.15M-$-62.51M
Operating income-$-76.94M-$-56.26M-$-43.57M-$-58.06M-$-63.01M
Total other income/expenses, net$4.16M$2.67M$1.36M-$-450K-$-650K
Income before tax-$-72.78M-$-53.59M-$-42.21M-$-58.51M-$-63.66M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-72.78M-$-53.59M-$-42.21M-$-58.51M-$-63.66M
Weighted average shares outstanding$67.4M$58.4M$48M$33.9M$28M
Weighted average diluted shares outstanding$67.4M$58.4M$48M$33.9M$28M
Balance sheet
20252024202320222021
Cash and short-term investments$80.7M$118M$44.4M$61.1M$28.6M
Net receivables$270K$0.00$0.00$0.00$60K
Inventory$140K$0.00$0.00$0.00$5.82M
Total current assets$83.4M$119.5M$45.3M$62.2M$36.6M
Property, plant and equipment, net$7.06M$8.32M$8.78M$10M$11.3M
Goodwill and intangible assets$3.37M$4.01M$4.68M$5.34M$6.01M
Long-term investments$0.00$0.00$1.89M-$-2.73M-$-3.25M
Total non-current assets$12.7M$13M$13.8M$15.7M$17.6M
Total assets$96.1M$132.5M$59.2M$77.9M$54.3M
Accounts payable$2.78M$1.67M$1.84M$1.57M$2.9M
Short-term debt$1.57M$1.35M$1.06M$1.81M$1.21M
Deferred revenue$0.00$0.00$0.00$0.00$20K
Total current liabilities$7.92M$10.1M$6.71M$5.98M$8.52M
Long-term debt$5.96M$7.54M$8.09M$74.1M$10M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.54M$7.54M$8.09M$74.1M$10M
Capital lease obligations$5.96M$8.9M$9.14M$10M$10.8M
Total liabilities$15.5M$17.6M$14.8M$80.1M$18.6M
Common stock$70K$70K$60K$40K$30K
Retained earnings-$-463.28M-$-390.5M-$-336.92M-$-294.7M-$-236.2M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$80.7M$114.9M$44.4M-$-2.25M$35.7M
Total investments$0.00$0.00$1.89M-$-2.73M-$-3.25M
Total debt$7.53M$8.9M$9.14M$76M$11.3M
Net debt-$-73.2M-$-109.14M-$-35.22M$14.8M-$-17.36M
Cash flow statement
20252024202320222021
Net income-$-72.78M-$-53.59M-$-42.21M-$-58.51M-$-63.66M
Depreciation and amortization$1.07M$1.18M$1.21M$1.35M$1.15M
Stock-based compensation$21.5M$13.6M$7.18M$5.19M$14.6M
Change in working capital-$-5.02M$2.47M$770K-$-3.72M-$-6.2M
Accounts receivable-$-270K$50K$110K$20K-$-60K
Inventory-$-140K$0.00$0.00-$-2.65M-$-5.82M
Accounts payable$1.13M-$-200K$260K-$-1.3M$1.16M
Net cash provided by operating activities-$-54.12M-$-36.34M-$-33.04M-$-47.01M-$-54.1M
Investments in property, plant and equipment-$-320K-$-120K-$-120K-$-400K-$-440K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-340K-$-120K-$-120K-$-400K$7.56M
Common stock issued$17.2M$59.7M$16.4M$14.9M$56.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.2M$110.1M$16.4M$79.9M$62.7M
Net change in cash-$-37.3M$73.7M-$-16.77M$32.5M$16.2M
Cash at end of period$80.7M$118M$44.4M$61.1M$28.6M
Operating cash flow-$-54.12M-$-36.34M-$-33.04M-$-47.01M-$-54.1M
Capital expenditure-$-320K-$-120K-$-120K-$-400K-$-440K
Free cash flow-$-54.44M-$-36.47M-$-33.16M-$-47.41M-$-54.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pulse Biosciences, Inc.

        Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.

        CEO
        Paul Arthur LaViolette
        Employees
        116
        Beta
        1.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Pulse Biosciences, Inc. (PLSE)?

        InvestorsCraft does not currently publish an intrinsic value for PLSE. How the IC value is calculated.

        Is PLSE undervalued?

        InvestorsCraft does not publish an undervaluation signal for PLSE at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.